Immunocore Quarterly Cash Flow Statement
NASDAQ: IMCRHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Immunocore free cash flow
In the quarter ended Jun 30, 2026, Immunocore generated $15.9 million of operating cash flow and spent $786,000 on capital expenditures. That left free cash flow of $15.1 million, a free-cash-flow margin of 13.1% of revenue. Free cash flow was down 40.7% from the prior year's $25.6 million.
Summary generated from market data by MetaCap's automated system. Methodology
Immunocore cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -808.00K | 12.97M | -30.06M | -177.00K | -10.30M | 5.02M | -23.77M | 8.74M | -11.62M | -24.44M | -19.73M | 906.00K |
| Net Income growth (YoY) | — | +158.23% | — | -102.03% | — | — | — | +864.24% | — | — | — | — |
| Depreciation & Amortization | 1.03M | 948.00K | 834.00K | 798.00K | 780.00K | 854.00K | 1.17M | 1.03M | 992.00K | 1.01M | 1.03M | 1.08M |
| Stock-Based Compensation | 9.40M | 6.30M | 8.34M | 9.84M | 10.03M | 9.49M | 8.67M | 6.56M | 10.00M | 8.96M | 7.19M | 8.20M |
| Change in Working Capital | 6.68M | -10.26M | -1.44M | -11.42M | -6.10M | 2.60M | 2.93M | -6.76M | 3.25M | -8.72M | -18.47M | -4.37M |
| Operating Cash Flow | 15.93M | -13.78M | -32.66M | -4.46M | 25.96M | 435.00K | -13.95M | 21.13M | 23.47M | -4.59M | -17.73M | 10.09M |
| Capital Expenditures | -786.00K | -1.78M | -2.88M | -748.00K | -414.00K | -298.00K | -3.58M | -828.00K | -331.00K | -430.00K | -817.00K | -212.00K |
| Investing Cash Flow | -786.00K | 4.22M | -880.00K | 5.25M | -30.41M | 9.70M | -3.54M | -828.00K | -350.33M | -430.00K | -817.00K | -212.00K |
| Financing Cash Flow | 16.48M | 656.00K | 4.28M | 1.87M | 3.67M | 2.55M | -51.51M | 198.00K | -818.00K | 396.01M | 6.25M | 10.38M |
| Net Change in Cash | 31.63M | -8.90M | -29.25M | 2.66M | -780.00K | 12.69M | -69.00M | 20.50M | -327.68M | 391.00M | -12.30M | 20.25M |
| Free Cash Flow | 15.14M | -15.56M | -35.53M | -5.20M | 25.55M | 137.00K | -17.54M | 20.30M | 23.14M | -5.02M | -18.55M | 9.88M |
This table shows 12 quarterly periods of Immunocore's cash flow statement, from Q2 2026 back to Q3 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow IMCR's reporting calendar. What is a cash flow statement?